Education
About Us
Working with TipRanks
Follow Us
Daiichi Sankyo Company Limited (JP:4568)
:4568
Carboplatin, Etoposide, Atezolizumab, Gocatamig, I-Dxd, Rescue Medications
Small Cell Lung Cancer Extensive Stage
Phase I/II
Not Yet Recruiting
A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)
Nov 10, 2025
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Daiichi Sankyo Company Limited (4568) have in its pipeline
4568 is currently developing the following drugs: Cetuximab, Patritumab Deruxtecan, Sacituzumab Tirumotecan, Rescue Medications, Mk-1084, Carboplatin, Etoposide, Atezolizumab, Gocatamig, I-Dxd, Rescue Medications, Docetaxel, Datopotamab Deruxtecan (Dato-Dxd). These drug candidates are in various stages of clinical development as the company works toward FDA approval.